#1 Clinical Trials Search in Europe

Pirtobrutinib

Pirtobrutinib, also known as LOXO-305 or LY3527727, is an innovative oral medication being studied in clinical trials for various B-cell cancers. This article explores the ongoing research on pirtobrutinib, its potential benefits, and its role in treating conditions such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL).

Table of Contents

What is Pirtobrutinib?

Pirtobrutinib, also known as LOXO-305 or LY3527727, is a new medication being studied for the treatment of various blood cancers[1][2]. It belongs to a class of drugs called Bruton Tyrosine Kinase (BTK) inhibitors. BTK inhibitors work by blocking a protein that helps cancer cells survive and grow[1].

What makes pirtobrutinib unique is that it is a noncovalent BTK inhibitor. This means it binds to the BTK protein in a different way than other drugs in its class, potentially making it more effective and less likely to cause resistance in cancer cells[1].

What Conditions Does Pirtobrutinib Treat?

Pirtobrutinib is being studied to treat several types of blood cancers, including:

  • Chronic Lymphocytic Leukemia (CLL): A slow-growing cancer of the blood and bone marrow[3]
  • Small Lymphocytic Lymphoma (SLL): A type of cancer very similar to CLL, but primarily affecting the lymph nodes[3]
  • Waldenström Macroglobulinemia (WM): A rare type of blood cancer that starts in the white blood cells[1]
  • Mantle Cell Lymphoma: A rare, aggressive type of B-cell non-Hodgkin lymphoma[4]
  • Marginal Zone Lymphoma: A slow-growing type of non-Hodgkin lymphoma[5]

It’s important to note that while pirtobrutinib has shown promise in treating these conditions, it is still being studied and is not yet approved for all of these uses[1].

How Does Pirtobrutinib Work?

Pirtobrutinib works by targeting and blocking a protein called Bruton Tyrosine Kinase (BTK). This protein is essential for the survival and growth of certain types of cancer cells, particularly those involved in blood cancers[1].

By inhibiting BTK, pirtobrutinib can:

  • Stop cancer cells from growing and dividing
  • Prevent cancer cells from surviving
  • Potentially cause cancer cells to die

Unlike some other BTK inhibitors, pirtobrutinib binds to the BTK protein in a noncovalent way. This means it can potentially overcome resistance that some patients develop to other BTK inhibitors, making it a promising option for patients who have not responded well to previous treatments[1].

Current Clinical Trials

Pirtobrutinib is currently being studied in several clinical trials to evaluate its safety and effectiveness. Some of the key trials include:

  • A study combining pirtobrutinib with venetoclax for Waldenström Macroglobulinemia[1]
  • A trial testing different doses of pirtobrutinib in patients with relapsed or refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[3]
  • A study of pirtobrutinib combined with rituximab for newly diagnosed Marginal Zone Lymphoma[5]
  • A trial of fixed-duration therapy with pirtobrutinib and obinutuzumab for previously untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[6]

These trials aim to determine the best dosing, potential side effects, and effectiveness of pirtobrutinib in various blood cancers.

How is Pirtobrutinib Administered?

Pirtobrutinib is taken orally, usually as a tablet, once daily[1][5]. The exact dosage and duration of treatment may vary depending on the specific condition being treated and the individual patient’s response.

In some clinical trials, pirtobrutinib is being studied in combination with other cancer medications. For example:

  • With venetoclax for Waldenström Macroglobulinemia[1]
  • With rituximab for Marginal Zone Lymphoma[5]
  • With obinutuzumab for Chronic Lymphocytic Leukemia[6]

The duration of treatment can range from fixed periods (like 12 cycles or approximately 1 year) to continuous treatment until disease progression or unacceptable side effects occur[6].

Potential Side Effects

As pirtobrutinib is still in clinical trials, the full range of potential side effects is not yet known. However, researchers are closely monitoring participants for any adverse reactions[7].

Common side effects of BTK inhibitors as a class may include:

  • Fatigue
  • Diarrhea
  • Bruising or bleeding more easily
  • Increased risk of infections

It’s important to note that not everyone experiences side effects, and the severity can vary from person to person. If you’re participating in a clinical trial or receiving pirtobrutinib as part of your treatment, your healthcare team will closely monitor you for any side effects and adjust your treatment as necessary[7].

Future Research and Potential

Pirtobrutinib shows promising potential in the treatment of various blood cancers, particularly for patients who have not responded well to other treatments. Ongoing research is focusing on:

  • Determining the most effective dosage and treatment duration[3]
  • Evaluating its effectiveness in combination with other cancer drugs[1][5][6]
  • Assessing its safety profile in different patient populations[8][9]
  • Exploring its potential in treating newly diagnosed patients, not just those with relapsed or refractory disease[6]

As research continues, pirtobrutinib may become an important treatment option for patients with various types of blood cancers, offering hope for improved outcomes and quality of life.

Aspect Details
Drug Name Pirtobrutinib (LOXO-305, LY3527727)
Drug Class Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor
Administration Oral, daily dosing
Target Conditions CLL, SLL, MCL, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma
Key Clinical Trials Phase II studies in relapsed/refractory CLL/SLL, newly diagnosed Marginal Zone Lymphoma
Primary Outcomes Overall Response Rate (ORR), Pharmacokinetics (PK) parameters
Secondary Outcomes Progression-Free Survival (PFS), Duration of Response (DoR), Overall Survival (OS)
Safety Studies Evaluations in participants with impaired liver and kidney function
Expanded Access Available for eligible patients with previously treated B-cell cancers

FAQ

  • What is pirtobrutinib and how does it work? Pirtobrutinib is a first-in-class, oral noncovalent Bruton tyrosine kinase (BTK) inhibitor. It works by blocking the BTK enzyme, which is important for the growth and survival of certain types of B-cell cancers.
  • What types of cancers is pirtobrutinib being studied for? Pirtobrutinib is being investigated for various B-cell cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, and marginal zone lymphoma.
  • How is pirtobrutinib administered? Pirtobrutinib is administered orally, typically as a daily dose. The exact dosage may vary depending on the specific clinical trial or treatment protocol.
  • What are some of the potential benefits of pirtobrutinib? Pirtobrutinib has shown promise in treating patients with relapsed or refractory B-cell cancers, particularly those who have previously received other BTK inhibitors. It may offer an alternative treatment option for patients who have not responded well to other therapies.
  • Are there any ongoing expanded access programs for pirtobrutinib? Yes, there is an expanded access program for eligible participants with previously treated B-cell cancers who are ineligible for ongoing pirtobrutinib clinical trials. Treating physicians can contact the program administrators to determine if a patient meets the criteria for inclusion.

Ongoing Clinical Trials on Pirtobrutinib

  • A Study Comparing BGB-16673 to Pirtobrutinib for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Has Returned or Not Responded

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium France Germany Italy The Netherlands +4

  • Study of Glofitamab and Pirtobrutinib Treatment in Patients with Mantle Cell Lymphoma Who Have Failed Previous Therapy and in Previously Untreated Patients

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany Norway Spain Sweden

  • Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal Spain

  • Study on the Safety and Effectiveness of Pirtobrutinib for Adults with Immune Thrombocytopenia

    Recruiting

    1
    Investigated drugs:
    Denmark France Italy Norway Poland Spain

  • Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

  • Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Hungary The Netherlands +1

  • Study Comparing Pirtobrutinib and Ibrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Hungary +3

  • Evaluating the efficacy of pirtobrutinib and epcoritamab in patients with untreated Richter transformation of chronic lymphocytic leukemia

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Denmark Germany Ireland

  • A study to evaluate the effectiveness of pirtobrutinib in elderly and frail patients with mantle cell lymphoma who have not yet received treatment.

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of pirtobrutinib combined with immuno-chemotherapy for previously untreated patients with symptomatic chronic lymphocytic leukemia

    Not yet recruiting

    1 1 1
    Investigated drugs:
    France

Glossary

  • Bruton Tyrosine Kinase (BTK): An enzyme that plays a crucial role in the development and function of B cells, a type of white blood cell. BTK is often overactive in certain B-cell cancers, making it a target for cancer treatments.
  • Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects the blood and bone marrow, causing an overproduction of abnormal white blood cells called lymphocytes.
  • Small Lymphocytic Lymphoma (SLL): A type of non-Hodgkin lymphoma that affects the lymph nodes and is very similar to CLL, but with slightly different characteristics.
  • Mantle Cell Lymphoma (MCL): A rare and aggressive type of B-cell non-Hodgkin lymphoma that typically affects lymph nodes and other organs.
  • Waldenström's Macroglobulinemia: A rare type of blood cancer that begins in the white blood cells and overproduces abnormal proteins called monoclonal immunoglobulins.
  • Marginal Zone Lymphoma: A slow-growing type of non-Hodgkin lymphoma that develops from B cells in the marginal zone of lymphoid tissue.
  • Relapsed/Refractory (R/R): Refers to cancer that has returned after treatment (relapsed) or has not responded to initial treatment (refractory).
  • Overall Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.

References

  1. https://clinicaltrials.gov/study/NCT05734495
  2. https://clinicaltrials.gov/study/NCT06258174
  3. https://clinicaltrials.gov/study/NCT06588478
  4. https://clinicaltrials.gov/study/NCT05172700
  5. https://clinicaltrials.gov/study/NCT06390956
  6. https://clinicaltrials.gov/study/NCT06333262
  7. https://clinicaltrials.gov/study/NCT06181006
  8. https://clinicaltrials.gov/study/NCT06190691
  9. https://clinicaltrials.gov/study/NCT06190678